Tech Company Financing Transactions
eGenesis Funding Round
eGenesis closed a $125 million Series C funding round on 3/3/2021. Investors included Alta Partners, Altium Capital and Arch Venture Partners.
Transaction Overview
Company Name
Announced On
3/3/2021
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series C
Investors
Arch Venture Partners (Steven Gillis)
Proceeds Purpose
The company intends to use the funds to bring its lead programs in kidney and islet cell transplant into human proof-of-concept studies and continue to develop its proprietary gene-editing platform and scaling of GMP production.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 Technology Sq. 301
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Sekhri
Chief Operating Officer
Peter Hanson
VP - Bus. Development
Jennifer Bergheiser
VP - Bus. Development
Ariel Jasie
VP - Human Resources
Elizabeth Roberts
VP - R & D
Michael Curtis
VP - Regulatory Affairs
David Carmel
Browse more venture capital transactions:
Prev: 3/3/2021: Presage Biosciences venture capital transaction
Next: 3/3/2021: Reperio Health venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs